uniQure Gene Therapy Significantly Slows Huntington Disease Progression

Abstract

Get full access to this article

View all access options for this article.

References

uniQure. uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease. 2025. Available from: https://uniqure.gcs-web.com/node/12261/pdf [Last accessed: October 5, 2025].

Capsida Therapeutics. A Letter to the STXBP1 Community. 2025. Available from: https://capsida.com/a-letter-to-the-stxbp1-community/ [Last accessed: October 5, 2025].

Chiesi Group and Arbor Biotechnologies. Chiesi Group and Arbor Biotechnologies Announce a Global Strategic Partnership to Develop Novel Rare Disease Gene Editing Programs. 2025. Available from: https://www.globenewswire.com/news-release/2025/10/06/3161565/0/en/Chiesi-Group-and-Arbor-Biotechnologies-Announce-a-Global-Strategic-Partnership-to-Develop-Novel-Rare-Disease-Gene-Editing-Programs.html [Last accessed: October 6, 2025].

Rocket Pharmaceuticals. Form 8-K Current Report. 2025. Available from: https://ir.rocketpharma.com/static-files/31ad7573-82d3-4741-9ffb-58083254caf9 [Last accessed: October 5, 2025].

Taysha Gene Therapies. Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome. 2025. Available from: https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-fda-breakthrough-therapy [Last accessed: October 5, 2025].

Opus Genetics. Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5). 2025. Available from: https://ir.opusgtx.com/press-releases/detail/501/opus-genetics-reports-positive-pediatric-data-from-opgx-lca5-phase-12-trial-in-leber-congenital-amaurosis-type-5-lca5 [Last accessed: October 5, 2025].

Grinstein

. Braille to Sight: Opus Genetics’ Gene Therapy Treats Rare Childhood Blindness. Inside Precision Medicine, 2025. Available from: https://www.insideprecisionmedicine.com/topics/precision-medicine/braille-to-sight-opus-genetics-gene-therapy-treats-rare-childhood-blindness/

Ocugen. Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea. 2025. Available from: https://ir.ocugen.com/news-releases/news-release-details/ocugen-inc-and-kwangdong-pharmaceutical-co-ltd-complete-license [Last accessed: October 5, 2025].